AHA 2017:亚洲科学家终于有证据证明高剂量他汀类药物比低剂量更加安全有效!

2017-11-15 枫丹白露 来宝网

多年来,亚洲医生还没有一个有力的证据,证明美国医生已经表明的高剂量他汀类药物可以降低患者的心脏病风险的论断。但周一发布的一项大型新研究就是这样做的。

在日本患者中,高剂量他汀类药物比低剂量更有效】多年来,亚洲医生还没有一个有力的证据,证明美国医生已经表明的高剂量他汀类药物可以降低患者的心脏病风险的论断。但周一发布的一项大型新研究就是这样做的。

加州大学洛杉矶分校David Geffen医学院的心脏病学教授Karol E. Watson博士说:“在亚洲患者中,大量使用高剂量他汀类药物是不太情愿的。 “这个试验应该让人安心,这个策略是安全的,有很好的耐受性,是有益的。”

研究人员在美国心脏协会年度科学会议上介绍了他们的研究成果,为12000多名日本冠心病患者提供了他汀类药物。他们开始给所有患者每天1毫克剂量的匹伐他汀共4周。

然后,在最初的四周后,低密度脂蛋白(所谓的“坏”胆固醇)降低到130毫克/分以下的患者在随后的五年中随机接受低剂量或高剂量的匹伐他汀。归根结底,6,214例接受了1毫克的剂量,6,199例接受了4毫克的剂量。

服用较高剂量的患者死于心血管事件较少,非致死性心脏病发作和中风引起的发病情况较少,因胸痛不稳引起的住院治疗较少:高剂量患者为4.3%,低剂量患者为5.4%。

百分之八十三的患者是男性,平均年龄为68岁。研究人员表示,血压和糖尿病控制良好。

该研究的主要作者之一,博士,医学博士Hiroaki Shimokawa说,日本医生一直不愿意使用高剂量他汀类药物,因为亚洲患者缺乏证据证明这样做安全。他是日本仙台东北大学医学研究院心血管内科主任。

他说,这个试验提供了证据。

原始出处:

High-dose statin drugs were more effective than low doses in Japanese patients. American Heart Association News Stories, November 13th, 2017.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942081, encodeId=224a19420817a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Feb 12 17:14:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044485, encodeId=e6df204448568, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Nov 15 13:14:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267606, encodeId=c67b126e606f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 17 03:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480465, encodeId=034f148046536, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 17 03:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2018-02-12 amy0550
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942081, encodeId=224a19420817a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Feb 12 17:14:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044485, encodeId=e6df204448568, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Nov 15 13:14:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267606, encodeId=c67b126e606f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 17 03:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480465, encodeId=034f148046536, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 17 03:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942081, encodeId=224a19420817a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Feb 12 17:14:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044485, encodeId=e6df204448568, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Nov 15 13:14:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267606, encodeId=c67b126e606f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 17 03:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480465, encodeId=034f148046536, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 17 03:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2017-11-17 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942081, encodeId=224a19420817a, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Feb 12 17:14:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044485, encodeId=e6df204448568, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Nov 15 13:14:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267606, encodeId=c67b126e606f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 17 03:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480465, encodeId=034f148046536, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 17 03:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]

相关资讯

N Engl J Med:研究揭示降血脂药他汀类对糖尿病患者的影响!

根据11月1日在线发表在“新英格兰杂志”上的一项研究,对于1型糖尿病和白蛋白排泄水平高的青少年,血管紧张素转换酶(ACE)抑制剂和他汀类药物都不会随着时间的推移而改变白蛋白与肌酸酐的比例。

GW-ICC2017:名家云集:共话动脉粥样硬化与血脂管理策略

在第二十八届心长城国际心脏病学会议(GW-ICC 2017)上,专门开辟了一场”动脉粥样硬化(AS)与血脂管理论坛”,邀请多位心血管著名专家一起讨论AS和血脂管理中的热点问题,再次引起众多专家学者对血脂全面管理问题的深刻思考。对此,本次会议的精彩内容汇总如下。

研究显示他汀类对心脏病和中风患者表现出良好的治疗效果!

根据盐湖城山间医疗中心心脏研究所的一项最新研究显示,既往有心脏病发作史或中风病史的患者,出院后使用降胆固醇药物治疗的效果会更好。

Int J Cardiol:他汀类药物对RA患者新发ACS的预防效果如何?

该研究的结果表明他汀类药物治疗与RA患者新发ACS的发生率较低有关,其有益效应存在剂量反应。

他汀类降脂药的六大“讲究”

他汀类药物是细胞内胆固醇合成限速酶的抑制剂,自1976年第一代他汀被研发至今,已走过了风风雨雨三十一年。现在,他汀类药物在降血脂、冠心病的一二级预防等方面均有着不可替代的作用,虽然他汀类药物有着“安全”“高效”等美誉,但此类药物应用时还是需要讲究一下的。

Brit J Gen Pract:如何应用他汀类药物才能实现很大程度的利大于弊?

伯明翰大学的一项研究发现,他汀类药物并不总是适用于最有益于他们的患者。